← HALOZYME THERAPEUTICS, INC.
| Annual Trend | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | |||||||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | |||||||||||
| Net Income (Loss) Attributable to Parent | ($103.0m) | $63.0m | ($80.3m) | ($72.2m) | $129.1m | $402.7m | $202.1m | $281.6m | $444.1m | $316.9m | |
| Depreciation, Depletion and Amortization | $2.4m | $2.2m | $2.4m | $4.1m | $3.3m | $3.0m | $6.5m | $11.1m | $10.3m | $11.4m | |
| Amortization of Debt Issuance Costs | $2.9m | $1.8m | $1.5m | — | — | — | — | — | — | — | |
| Amortization of Intangible Assets | — | — | — | — | $0 | $0 | $43.1m | $73.8m | $71.0m | $76.7m | |
| Share-based Payment Arrangement, Noncash Expense | $25.6m | $30.7m | $35.7m | $34.8m | $17.2m | $20.8m | $24.4m | $36.6m | $43.4m | $51.6m | |
| Share-based Payment Arrangement, Expense | $25.6m | $30.7m | $35.7m | $34.8m | $17.2m | $20.8m | $24.4m | $36.6m | $43.4m | $51.6m | |
| Impairment of Intangible Assets (Excluding Goodwill) | — | — | — | — | — | — | — | — | — | $48.7m | |
| Operating Lease, Impairment Loss | — | — | — | $1.1m | $577k | $0 | $0 | — | — | — | |
| Gain (Loss) on Disposition of Property Plant Equipment | ($8k) | ($46k) | ($5k) | ($1.4m) | $772k | $0 | ($129k) | ($611k) | ($1.5m) | ($2.6m) | |
| Gain (Loss) on Extinguishment of Debt | — | — | — | ($401k) | $0 | $0 | — | — | — | — | |
| Income Tax Expense (Benefit) | $1.2m | ($1.4m) | $537k | ($11k) | $217k | ($154.2m) | $46.8m | $66.7m | $113.0m | $150.0m | |
| Interest Expense Nonoperating | — | — | — | — | — | — | — | — | $18.1m | $18.1m | |
| Operating Lease, Expense | — | — | — | — | — | $2.0m | $3.3m | $9.3m | $8.6m | $9.4m | |
| Other Nonoperating Income (Expense) | — | $2.6m | $7.6m | $7.0m | $5.4m | $1.1m | $1.0m | $16.3m | $23.8m | $21.5m | |
| Changes in operating assets and liabilities: | |||||||||||
| Additional Financial Items | |||||||||||
| Increase (Decrease) in Accounts Receivable | ($16.7m) | $6.5m | ($11.6m) | $29.4m | $38.3m | ($6.8m) | $83.9m | $3.3m | $74.2m | $128.1m | |
| Increase (Decrease) in Inventories | $5.1m | ($9.5m) | $17.5m | $6.7m | $31.4m | ($7.4m) | $17.5m | $26.9m | $67.4m | ($2.6m) | |
| Proceeds from Stock Options Exercised | — | $14.0m | $16.3m | $16.5m | $66.2m | $16.6m | — | — | — | — | |
| Debt Securities, Available-for-sale, Realized Gain (Loss) | — | — | — | — | $0 | $0 | ($1.7m) | $0 | $7k | $171k | |
| Foreign Currency Transaction Gain (Loss), Unrealized | — | — | ($1k) | $0 | ($22k) | $26k | — | — | — | — | |
| Goodwill | — | — | — | — | — | — | $409.0m | $416.8m | $416.8m | $580.4m | |
| Induced Conversion of Convertible Debt Expense | — | — | — | $0 | $0 | $21.0m | $2.7m | $0 | $0 | $5.5m | |
| Net Cash Provided by (Used in) Operating Activities | ($50.4m) | $134.1m | ($49.5m) | ($85.4m) | $55.5m | $299.4m | $240.1m | $388.6m | $479.1m | $651.6m | |
| Cash flows from investing activities: | |||||||||||
| Payments to Acquire Property, Plant, and Equipment | $3.1m | $1.4m | $4.7m | $4.0m | $2.5m | $1.5m | $4.8m | $15.3m | $10.7m | $7.0m | |
| Payments to Acquire Businesses, Net of Cash Acquired | — | — | — | — | — | — | $999.1m | $0 | $0 | $726.0m | |
| Net Cash Provided by (Used in) Investing Activities | ($76.8m) | ($163.7m) | $2.5m | ($5.5m) | $78.4m | ($406.3m) | ($487.0m) | ($96.9m) | ($262.7m) | ($545.8m) | |
| Cash flows from financing activities: | |||||||||||
| Proceeds from Issuance of Common Stock | $0 | $134.9m | $0 | $0 | $63.4m | $12.5m | $14.1m | $7.9m | $31.1m | $21.8m | |
| Payments for Repurchase of Common Stock | — | $0 | $0 | $200.0m | $150.1m | $350.1m | $200.0m | $402.4m | $250.0m | $342.4m | |
| Net Cash Provided by (Used in) Financing Activities | $150.6m | $131.7m | ($63.8m) | $153.2m | ($106.3m) | $77.9m | $362.4m | ($408.0m) | ($218.9m) | ($85.2m) | |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect | $23.5m | $102.0m | ($110.8m) | $62.2m | $27.5m | ($29.0m) | $115.5m | ($116.3m) | ($2.5m) | $20.6m | |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | $23.5m | $169.2m | $58.4m | $120.7m | $148.2m | $119.2m | $234.7m | $118.4m | $115.8m | $136.4m | |
| Supplemental disclosure of cash flow information: | |||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating Activities | $3.9m | $20.3m | $16.9m | $9.0m | $6.5m | $3.3m | $6.1m | $11.4m | $10.6m | $11.4m | |
| Income Taxes Paid, Net | $1.4m | $3.0m | $220k | ($188k) | ($180k) | ($375k) | $16.2m | $31.8m | $80.6m | $134.6m |
Values abbreviated: b = billions, m = millions, k = thousands. Per share data in USD.